Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06JHV
|
|||
| Former ID |
DIB013320
|
|||
| Drug Name |
Flumatinib
|
|||
| Synonyms |
HH-GV-678
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.1; ICD-9: 205.1] | Phase 2 | [1] | |
| Company |
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H29F3N8O
|
|||
| Canonical SMILES |
CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5
|
|||
| InChI |
1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)
|
|||
| InChIKey |
BJCJYEYYYGBROF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 895519-90-1
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02511340) A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients. | |||
| REF 2 | Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.